A convenient screening method to differentiate phenolic skin whitening tyrosinase inhibitors from leukoderma-inducing phenols

Journal of Dermatological Science

Volumn 80, Issue 1, 2015, Pages 18-24

  Ito, Shosuke ^a   Wakamatsu, Kazumasa ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Melanocyte toxicity; Rhododendrol; Tyrosinase; Tyrosinase inhibitor; Whitening agent

Indexed keywords

2,2' DIHYDROXY 5,50 DI N PROPYLBIPHENYL; 4 N BUTYLRESORCINOL; 4 TERT BUTYLCATECHOL; 4 TERT BUTYLPHENOL; ARBUTIN; DEPIGMENTING AGENT; ELLAGIC ACID; MEQUINOL; MONOBENZONE; MONOPHENOL MONOOXYGENASE; PHENOL; POTASSIUM 4 METHOXYSALICYLATE; RASPBERRY KETONE; RHODODENDROL; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PHENOL DERIVATIVE; QUINONE DERIVATIVE;

ABSORPTION SPECTROSCOPY; ARTICLE; CATALYST; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEUKODERMA; LIPOPHILICITY; OXIDATION; PH; PRIORITY JOURNAL; SCREENING TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; HYPOPIGMENTATION; METABOLISM; ULTRAVIOLET SPECTROPHOTOMETRY;

ENZYME INHIBITORS; HYPOPIGMENTATION; MONOPHENOL MONOOXYGENASE; PHENOLS; QUINONES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84937859832     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2015.07.007     Document Type: Article

References (43)

1. Ito S., Wakamatsu K. Chemistry of mixed melanogenesis-pivotal roles of dopaquinone. Photochem. Photobiol. 2008, 84:582-592.
2. Ramsden C.A., Riley P.A. Tyrosinase the four oxidation states of the active site and their relevance to enzymatic activation, oxidation and inactivation. Bioorg. Med. Chem. 2014, 22:2388-2395.
3. Bolton J.L., Trush M.A., Penning T.M., Dryhurst G., Monks T.J. Role of quinones in toxicology. Chem. Res. Toxicol. 2000, 13:135-160.
4. Graham D.G., Tiffany S.M., Bell W.R., Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 1978, 14:644-653.
5. Westerhof W., Manini P., Napolitano A., d'Ischia M. The haptenation theory of vitiligo and melanoma rejection: a close-up. Exp. Dermatol. 2011, 20:92-96.
6. Nishigori C., Aoyama Y., Ito A., Suzuki K., Suzuki T., Tanemura A., et al. Guide for medical professionals (i.e., dermatologists) for the management of Rhododenol-induced leukoderma. J. Dermatol. 2015, 42:113-128.
7. Kasamatsu S., Hachiya A., Nakamura S., Yasuda Y., Fujimori T., et al. Depigmentation caused by application of the active brightening material, rhododendrol, is related to tyrosinase activity at a certain threshold. J. Dermatol. Sci. 2014, 76:16-24.
8. Sasaki M., Kondo M., Sato K., Umeda M., Kawabata K., Takahashi Y., et al. Rhododendrol, a depigmentation-inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism. Pigm. Cell Melanoma Res. 2014, 27:754-763.
9. Ito S., Yamashita T., Ojika M., Wakamatsu K. Tyrosinase-catalyzed oxidation of rhododendrol produces 2-methylchromane-6,7-dione, the putative ultimate toxic metabolite: implications for melanocyte toxicity. Pigm. Cell Melanoma Res. 2014, 27:744-753.
10. Ito S., Gerwat W., Kolbe L., Yamashita T., Ojika M., Wakamatsu K. Human tyrosinase is able to oxidize both enantiomers of rhododendrol. Pigm. Cell Melanoma Res. 2014, 27:1149-1153.
11. Tokura Y., Fujiyama T., Ikeya S., Tatsuno K., Aoshima M., Kasuya A., Ito T. Biochemical, cytological, and immunological mechanisms of rhododendrol-induced leukoderma. J. Dermatol. Sci. 2015, 77:146-149.
12. Ito S., Okura M., Nakanishi Y., Ojika M., Wakamatsu K., Yamashita T. Tyrosinase-catalyzed metabolism of rhododendrol (RD) in B16 melanoma cells: production of RD-pheomelanin and covalent binding with thiol proteins. Pigm. Cell Melanoma Res. 2015, 28:296-306.
13. Fukuda Y., Nagano M., Futatsuka M. Occupational leukoderma in workers engaged in 4-(p-hydroxyphenyl)-2-butanone manufacturing. J. Occup. Health 1998, 40:118-122.
14. Riley P.A. Hydroxyanisole depigmentation: in vivo studies. J. Pathol. 1969, 97:185-191.
15. Moridani M.Y. Biochemical basis of 4-hydroxyanisole induced cell toxicity towards B16-F0 melanoma cells. Cancer Lett. 2006, 243:235-245.
16. Nordlund J.J., Forget B., Kirkwood J., Lerner A.B. Dermatitis produced by applications of monobenzone in patients with active vitiligo. Arch. Dermatol. 1985, 121:1141-1144.
17. James O., Mayes R.W., Stevenson C.J. Occupational vitiligo induced by p-tert-butylphenol: a systemic disease?. Lancet 1977, 2:1217-1219.
18. Gellin G.A., Possick P.A., Perone V.B. Depigmentation from 4-tertiary butyl catechol -an experimental study. J. Invest. Dermatol. 1970, 55:190-197.
19. Jow T., Hantash B.M. Hydroquinone-induced depigmentation: case report and review of the literature. Dermatitis 2014, 25:e1-e5.
20. Lee S.Y., Baek N., Nam T.G. Natural, semisynthetic and synthetic tyrosinase inhibitors. J. Enzyme Inhib. Med. Chem. 2015, (16 Feb):1-13.
21. Maeda K., Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J. Pharmacol. Exp. Ther. 1996, 276:765-769.
22. Yoshimura M., Watanabe Y., Kasai K., Yamakoshi J., Koga T. Inhibitory effect of an ellagic acid-rich pomegranate extract on tyrosinase activity and ultraviolet-induced pigmentation. Biosci. Biotechnol. Biochem. 2005, 69:2368-2373.
23. Kolbe L., Mann W., Gerwat W., Batzer J., Ahlheit S., Scherner C., Wenck H., Stäb F. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. J Eur Acad Dermatol Venereol 2013, 27(Suppl. 1):19-23.
24. Fujiwara R., Yoshida Y., Aoki H., Sato K. A novel approach for whitening with potassium 4-methoxysalicylate. Fragrance J. 2008, 9:37-41. (in Japanese).
25. Nakamura K., Yoshida M., Uchiwa H., Kawa Y., Mizoguchi M. Down-regulation of melanin synthesis by a biphenyl derivative and its mechanism. Pigm. Cell Res. 2003, 16:494-500.
26. Cooksey C.J., Jimbow K., Land E.J., Riley P.A. Reactivity of orthoquinones involved in tyrosinase-dependent cytotoxicity: differences between alkylthio- and alkoxy-substituents. Melanoma Res. 1992, 2:283-293.
27. Land E.J., Ramsden C.A., Riley P.A. Tyrosinase autoactivation and the chemistry of ortho-quinone amines. Acc. Chem. Res. 2003, 36:300-308.
28. Sartori G., Maggi R., Bigi F., Arienti A., Casnati G., Bocelli G., Mori G. Oxidative coupling of dichloroaluminium phenolates: highly selective synthesis of hydroxylated bi- and tetraaryls. Tetrahedron 1992, 48:9483-9494.
29. Narita S., Ogura T., Usuki T. Synthesis of magnolignan, a new pigment lightening component, via a Suzuki-Miyaura reaction. J. Chem. 2013, 686242.
30. Verotta L., Orsini F., Pelizzoni F., Torri G., Rogers C.B. Polyphenolic glycosides from African Proteaceae. J. Nat. Prod. 1999, 62:1526-1531.
31. Naish S., Cooksey C.J., Riley P.A. Initial mushroom tyrosinase-catalysed oxidation product of 4-hydroxyanisole is 4-methoxy-ortho-benzoquinone. Pigm. Cell Res. 1988, 1:379-381.
32. Manini P., Napolitano A., Westerhof W., Riley P.A., d'Ischia M. A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity. Chem. Res. Toxicol. 2009, 22:1398-1405.
33. Thörneby-Andersson K., Sterner O., Hansson C. Tyrosinase-mediated formation of a reactive quinone from the depigmenting agents, 4-tert-butylphenol and 4-tert-butylcatechol. Pigm. Cell Res. 2000, 13:33-38.
34. Fukuda Y., Nagano M., Tsukamoto K., Futatsuka M. In vitro studies on the depigmenting activity of 4-(p-hydroxyphenyl)-2-butanone. J. Occup. Health 1998, 40:137-142.
35. Muñoz-Muñoz J.L., García-Molina M.M., García-Molina F., Varon R., García-Ruiz P.A., Rodríguez-López J.N., García-Cánovas F. Indirect inactivation of tyrosinase in its action on 4-tert-butylphenol. J. Enzyme Inhib. Med. Chem. 2014, 29:344-352.
36. Yang F., Sarangarajan R., Le Poole I.C., Medrano E.E., Boissy R.E. The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. J. Invest. Dermatol. 2000, 114:157-164.
37. Palumbo A., d'Ischia M., Misuraca G., Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim. Biophys. Acta 1991, 1073:85-90.
38. García-Molina M.M., Muñoz Muñoz J.L., Martinez-Ortiz F., Martinez J.R., García-Ruiz P.A., Rodriquez-López J.N., García-Cánovas F. Tyrosinase-catalyzed hydroxylation of hydroquinone, a depigmenting agent, to hydroxyhydroquinone: a kinetic study. Bioorg. Med. Chem. 2014, 22:3360-3369.
39. Stratford M.R.L., Ramsden C.A., Riley P.A. The influence of hydroquinone on tyrosinase kinetics. Bioorg. Med. Chem. 2012, 20:4364-4370.
40. Ramsden C.A., Riley P.A. Mechanistic aspects of the tyrosinase oxidation of hydroquinone. Bioorg. Med. Chem. Lett. 2014, 24:2463-2464.
41. Nihei K., Kubo I. Identification of oxidation product of arbutin in mushroom tyrosinase assay system. Bioorg. Med. Chem. Lett. 2003, 13:2409-2412.
42. Muñoz-Muñoz J.L., Garcia-Molina F., Garcia-Molina M., Tudela J., García-Cánovas F., Rodriguez-Lopez J.N. Ellagic acid: characterization as substrate of polyphenol oxidase. IUBMB Life 2009, 61:171-177.
43. Stratford M.R.L., Ramsden C.A., Riley P.A. Mechanistic studies of the inactivation of tyrosinase by resorcinol. Bioorg. Med. Chem. 2013, 21:1166-1173.